Technology
AACR 2023
Pear Bio immuno-oncology models have been validated further, and they have been used to test antibody-based and cell therapies.
ASCO 2022
Pear Bio has added immuno-oncology capabilities to our precision medicine platform. We can now track immune cell infiltration into patient-derived 3D tumor cultures using time-lapsed 3D microscopy.
AACR 2022
Pear Bio has developed a computational biology platform that is undergoing validation across multiple solid tumors, with early data on triple negative breast cancer.
Pear bio Cancer model platform
Pear Bio develops modular platforms combining 3D cell cultures, microscopy and computer vision to analyze cancer progression.